The Catalyst campus in Newcastle Helix serves as the global headquarters for TREAT-NMD, a leading network dedicated to accelerating the development of therapies for neuromuscular diseases. Hosted in a state-of-the-art science building adjacent to Newcastle University's research facilities, this site focuses on translational research, patient registries, and international collaboration to bridge the gap between laboratory discoveries and clinical applications specifically for rare neuromuscular disorders.
- Neuromuscular Disease Registries: Management of the TREAT-NMD Global Registry Network, including core datasets for Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), limb-girdle muscular dystrophies (LGMD), and spinal muscular atrophy (SMA), enabling natural history studies and trial readiness.
- Educational Programmes: Delivery of specialist masterclasses, conferences, and engagement events such as UK Neuromuscular Translational Research Conferences and Becker Education Days, training clinicians, researchers, and patient advocates.
- Therapeutic Development Support: Facilitation of drug development pipelines through partnerships with pharmaceutical companies, academic institutions like Newcastle University and the John Walton Muscular Dystrophy Research Centre (JWMDRC), and patient organisations.
- Clinical Trial Infrastructure: Coordination of care and trial site registries, standards harmonisation, and data enquiries to support over 100 international research centres.
- Patient Engagement and Resources: Development of multilingual guides, e-learning modules, and stakeholder meetings to empower patients and families in the UK and globally.
This campus's academic focus integrates research, education, and advocacy, fostering innovations that have advanced therapies like gene therapies and exon-skipping drugs for neuromuscular patients.
